<DOC>
	<DOCNO>NCT00000821</DOCNO>
	<brief_summary>To compare effect low-dose versus high-dose subcutaneous ( SC ) aldesleukin ( interleukin-2 ; IL-2 ) immunologic virologic marker HIV-infected patient . To compare effect monthly versus bimonthly administration SC IL-2 marker . Interleukin-2 protein naturally produce lymphocyte . In initial study , patient earlier stage HIV-1 infection tend tolerate SC IL-2 well advanced infection , high baseline CD4+ count tend derive great benefit .</brief_summary>
	<brief_title>Subcutaneously Administered Aldesleukin ( Interleukin-2 ; IL-2 ) Therapy HIV-Infected Patients</brief_title>
	<detailed_description>Interleukin-2 protein naturally produce lymphocyte . In initial study , patient earlier stage HIV-1 infection tend tolerate SC IL-2 well advanced infection , high baseline CD4+ count tend derive great benefit . Patients randomize one four treatment arm ; patient receive either low-dose high-dose SC IL-2 5 day either monthly bimonthly schedule approximately 6 month .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Inclusion Criteria Patients must : HIV positivity . CD4 count &gt; = 500 cells/mm3 . No history AIDSdefining opportunistic infection , malignancy mucocutaneous Kaposi 's sarcoma . Concurrent Medication : Required : Concurrent FDAapproved antiretroviral therapy ( AZT , ddI , ddC , d4T ) . Prior Medication : Required : FDAapproved antiretroviral therapy least 6 week prior study entry . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Significant cardiac , pulmonary , thyroid , renal , CNS disease . Prior Medication : Excluded : Prior IL2 . Systemic corticosteroid , chemotherapy , experimental therapy within 4 week prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Interleukin-2</keyword>
	<keyword>AIDS-Related Complex</keyword>
</DOC>